185 related articles for article (PubMed ID: 36975157)
21. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
22. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Verbeek MWC; Buracchi C; Laqua A; Nierkens S; Sedek L; Flores-Montero J; Hofmans M; Sobral de Costa E; Nováková M; Mejstrikova E; Barrena S; Kohlscheen S; Szczepanowski M; Kulis J; Oliveira E; Jugooa R; de Jong AX; Szczepanski T; Philippé J; van Dongen JJM; Orfao A; Brüggemann M; Gaipa G; van der Velden VHJ
Br J Haematol; 2022 Apr; 197(1):76-81. PubMed ID: 34881427
[TBL] [Abstract][Full Text] [Related]
24. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L
Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Wang Y; Xue YJ; Jia YP; Zuo YX; Lu AD; Zhang LP
Acta Haematol; 2023; 146(5):349-357. PubMed ID: 37212472
[TBL] [Abstract][Full Text] [Related]
26. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
[TBL] [Abstract][Full Text] [Related]
27. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
28. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract][Full Text] [Related]
29. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
31. Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With Clinical Outcome in Adult B-Cell Acute Lymphoblastic Leukemia: A Real-World Study Based on 486 Patients.
Liao H; Jiang N; Yang Y; Zhang X; Chen J; Lai H; Zheng Q
Arch Pathol Lab Med; 2023 Oct; 147(10):1186-1195. PubMed ID: 36508349
[TBL] [Abstract][Full Text] [Related]
32. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
Momen N; Tario J; Fu K; Qian YW
J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
34. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
35. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
[TBL] [Abstract][Full Text] [Related]
36. Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia.
Samardžić-Predojević J; Đurđević-Banjac B; Malčić-Zanić D
Acta Med Acad; 2023 Dec; 52(3):153-160. PubMed ID: 38407081
[TBL] [Abstract][Full Text] [Related]
37. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.
Locatelli F; Maschan A; Boissel N; Strocchio L; Alam N; Pezzani I; Brescianini A; Kreuzbauer G; Baruchel A
Pediatr Blood Cancer; 2022 Apr; 69(4):e29562. PubMed ID: 35044079
[TBL] [Abstract][Full Text] [Related]
38. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
39. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
Nedumannil R; Ritchie D; Bajel A; Ng AP; Harrison SJ; Westerman D
Eur J Haematol; 2023 Feb; 110(2):168-176. PubMed ID: 36321745
[TBL] [Abstract][Full Text] [Related]
40. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]